Analysts expect that Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) will post $3.90 earnings per share (EPS) for the current quarter, Zacks reports. Seven analysts have provided estimates for Jazz Pharmaceuticals’ earnings, with the highest EPS estimate coming in at $4.12 and the lowest estimate coming in at $3.44. Jazz Pharmaceuticals posted earnings of $3.64 per share during the same quarter last year, which suggests a positive year-over-year growth rate of 7.1%. The business is expected to issue its next quarterly earnings results on Tuesday, February 25th.
On average, analysts expect that Jazz Pharmaceuticals will report full-year earnings of $15.48 per share for the current fiscal year, with EPS estimates ranging from $14.83 to $15.93. For the next fiscal year, analysts forecast that the business will report earnings of $17.27 per share, with EPS estimates ranging from $15.57 to $19.45. Zacks’ earnings per share calculations are a mean average based on a survey of analysts that follow Jazz Pharmaceuticals.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, November 5th. The specialty pharmaceutical company reported $4.10 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.19 by $0.91. The company had revenue of $537.70 million for the quarter, compared to analysts’ expectations of $523.92 million. Jazz Pharmaceuticals had a return on equity of 27.99% and a net margin of 29.61%. The firm’s revenue was up 14.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.58 earnings per share.
Several analysts have issued reports on JAZZ shares. Zacks Investment Research downgraded shares of Jazz Pharmaceuticals from a “buy” rating to a “hold” rating and set a $138.00 target price on the stock. in a research note on Friday, September 13th. HC Wainwright reissued a “hold” rating and set a $147.00 target price on shares of Jazz Pharmaceuticals in a research note on Monday. TheStreet downgraded shares of Jazz Pharmaceuticals from a “b-” rating to a “c+” rating in a research note on Friday, October 18th. BidaskClub downgraded shares of Jazz Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, October 11th. Finally, Sanford C. Bernstein reissued a “market perform” rating and set a $150.00 target price on shares of Jazz Pharmaceuticals in a research note on Monday, October 14th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and nine have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $165.71.
NASDAQ JAZZ opened at $130.88 on Friday. The business’s fifty day moving average is $124.79 and its two-hundred day moving average is $131.73. The company has a debt-to-equity ratio of 0.56, a quick ratio of 3.71 and a current ratio of 3.89. Jazz Pharmaceuticals has a 1 year low of $113.52 and a 1 year high of $154.44. The stock has a market capitalization of $7.36 billion, a P/E ratio of 10.69, a P/E/G ratio of 1.02 and a beta of 1.09.
In other news, CEO Bruce C. Cozadd sold 500 shares of the company’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $130.00, for a total value of $65,000.00. Following the transaction, the chief executive officer now directly owns 311,855 shares of the company’s stock, valued at $40,541,150. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 4.30% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. increased its stake in shares of Jazz Pharmaceuticals by 2.2% in the second quarter. Charles Schwab Investment Management Inc. now owns 457,226 shares of the specialty pharmaceutical company’s stock worth $65,183,000 after acquiring an additional 9,797 shares during the last quarter. HBK Sorce Advisory LLC bought a new stake in Jazz Pharmaceuticals in the second quarter worth $324,000. CENTRAL TRUST Co boosted its holdings in Jazz Pharmaceuticals by 256.4% in the second quarter. CENTRAL TRUST Co now owns 1,522 shares of the specialty pharmaceutical company’s stock worth $210,000 after purchasing an additional 1,095 shares in the last quarter. Chicago Equity Partners LLC boosted its holdings in Jazz Pharmaceuticals by 152.4% in the second quarter. Chicago Equity Partners LLC now owns 16,760 shares of the specialty pharmaceutical company’s stock worth $2,389,000 after purchasing an additional 10,120 shares in the last quarter. Finally, Zacks Investment Management bought a new stake in Jazz Pharmaceuticals in the second quarter worth $1,626,000. 87.74% of the stock is currently owned by institutional investors and hedge funds.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Read More: Do You Need a Fiduciary?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.